ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02610127
Recruitment Status : Recruiting
First Posted : November 20, 2015
Last Update Posted : March 26, 2018
Sponsor:
Collaborator:
Baxalta Innovations GmbH, now part of Shire
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )

Brief Summary:
The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.

Condition or disease Intervention/treatment
Acquired Hemophilia A Biological: OBIZUR

Detailed Description:

This study is a multi-center, uncontrolled, open-label, non-interventional post-marketing safety surveillance study to describe the use of Obizur in patients with acquired hemophilia A (AHA), and secondarily, where data are available, to describe the hemostatic effectiveness and immunogenicity of Obizur.

Patients should be enrolled at the earliest possible time point after initiating Obizur.

In an attempt to collect safety and utilization data on patients treated with Obizur since Food and Drug Administration (FDA) approval in October 2014, Baxalta will make an effort to identify all persons treated with Obizur and to collect data for as many patients as possible.


Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Actual Study Start Date : December 30, 2015
Estimated Primary Completion Date : August 1, 2019
Estimated Study Completion Date : August 1, 2019


Group/Cohort Intervention/treatment
OBIZUR - Prospective Participants
Participants enrolled and treated with Obizur after the prospective study start date
Biological: OBIZUR
Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
Other Names:
  • rpFVIII
  • Recombinant pFVIII
  • Antihemophilic Factor (Recombinant)
  • Porcine Sequence

OBIZUR - Retrospective Participants
Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date
Biological: OBIZUR
Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
Other Names:
  • rpFVIII
  • Recombinant pFVIII
  • Antihemophilic Factor (Recombinant)
  • Porcine Sequence




Primary Outcome Measures :
  1. Incidence of therapy-related SAEs and level of severity [ Time Frame: Throughout the study period of approximately 4 years ]

Secondary Outcome Measures :
  1. Hemostatic effectiveness assessment for resolution of bleeding [ Time Frame: Throughout the study period, up to approximately 4 years ]
    Determined as either bleeding stopped or did not stop

  2. Time to bleeding resolution, participant study termination, or switch to another treatment [ Time Frame: Throughout the study period, up to approximately 4 years ]
  3. Number of Obizur units/kg required for control of bleeding [ Time Frame: Throughout the study period, up to approximately 4 years ]
  4. Number of Obizur infusions required for control of bleeding [ Time Frame: Throughout the study period, up to approximately 4 years ]
  5. Titer of newly recognized anti-porcine Factor VIII (anti-pFVIII) neutralizing antibodies (inhibitors) or increase in titer of anti-pFVIII inhibitors from baseline and changes over time. [ Time Frame: Throughout the study period of approximately 4 years ]
  6. Impact of the inhibitor on hemostatic efficacy and any associated clinical manifestations. [ Time Frame: Throughout the study period of approximately 4 years ]
  7. Occurrence of hypersensitivity reactions [ Time Frame: Throughout the study period of approximately 4 years ]
  8. Occurrence of any thrombogenic event [ Time Frame: Throughout the study period of approximately 4 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participant is ≥18 years of age at the time of informed consent.
  2. Participant has AHA, and is being treated/was treated with Obizur.
  3. Participant or the participant's legally authorized representative is willing and able to provide informed consent, unless informed consent is not required

Exclusion Criteria:

  1. Participant has a known anaphylactic reaction to the active substance, to any of the excipients, or to hamster protein.
  2. Participant has a concomitant bleeding disorder(s) other than acquired hemophilia A (AHA).
  3. Participant has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02610127


Contacts
Contact: Oliver Mauric, MSc +43 1 20100 247 6826 oliver.mauric@shire.com

Locations
United States, Colorado
University of Colorado Health Recruiting
Aurora, Colorado, United States, 80045
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
United States, Georgia
Emory University School of Medicine Recruiting
Atlanta, Georgia, United States, 30322
United States, Illinois
Bleeding and Clotting Disorders Institute Recruiting
Peoria, Illinois, United States, 61615
United States, Indiana
Indiana Hemophilia and Thrombosis Center Recruiting
Indianapolis, Indiana, United States, 46260
United States, Iowa
University of Iowa Hospitals & Clinics Recruiting
Iowa City, Iowa, United States, 52242
United States, Louisiana
Tulane University Hospital & Clinics Recruiting
New Orleans, Louisiana, United States, 70112
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Michigan State University Recruiting
East Lansing, Michigan, United States, 48823
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Comprehensive Cancer Center of Wake Forest Unversity Recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pennsylvania Health System Recruiting
Philadelphia, Pennsylvania, United States, 19104
United States, Utah
University of Utah Health Sciences Center Recruiting
Salt Lake City, Utah, United States, 84132
United States, Wisconsin
Blood Center of Southeast Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53225
Sponsors and Collaborators
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire
Investigators
Study Director: Lydia Abad Franch, MD Baxalta now part of Shire

Responsible Party: Baxalta now part of Shire
ClinicalTrials.gov Identifier: NCT02610127     History of Changes
Other Study ID Numbers: 241302
First Posted: November 20, 2015    Key Record Dates
Last Update Posted: March 26, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants